Scientists at the University of Edinburgh have developed nanorobots that can manage brain hemorrhages caused by aneurysms. These miniaturized devices, twenty times smaller than a human red blood cell, are designed to accurately and safely treat aneurysms, which cause around 500,000 deaths worldwide each year.
The nanorobots, which contain blood-stopping drugs, are coated with a protective shell that melts at a predetermined temperature. In laboratory tests, hundreds of billions of these robots have been injected into an artery and guided by magnets toward an aneurysm. Once they reach their target, they form a cluster and heat up, releasing a protein that promotes clot formation and stops bleeding.
The technology could replace traditional treatments, such as the use of metal catheters and stents, and reduce the risk of implant rejection and complications from anticoagulant drugs. Further trials are expected to bring this innovation closer to clinical application.
Medicine
Biotech
7
0
0
Share
Comments
Recommended
Pavel Ryzhikh
80 subscribers
10 months ago
Subscribe
US scientists have found a new way in preserving organs for transplantation
Scientists from the Universities of Minnesota and California Riverside have developed a new two-step “nanoheating” process. According to the authors of the project, it could fundamentally change the approach to organ transplantation.
This innovative technique safely heats frozen tissue using nanoscale magnetic rods. The researchers demonstrated that clusters of iron oxide nanoparticles exposed t
Show more
Medicine
Biotech
11
0
0
Share
Pavel Ryzhikh
80 subscribers
10 months ago
Subscribe
New insulin delivered once a week has demonstrated efficacy
At the annual meeting of the European Association for the Study of Diabetes 2024 in Madrid, the results of clinical trials of the new insulin efsitor, which is administered once a week, were presented. The tests showed that the new drug is as effective as degludec, which is administered daily.
The trials were conducted in the format of evaluating the new insulin compared to the existing insulin.